Pulmonary Embolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Pulmonary embolism pipeline market research report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Key Targets in the Pulmonary Embolism Pipeline Market

The key targets in the pulmonary embolism pipeline market are Plasminogen, Coagulation Factor X, Coagulation Factor XI, Platelet Glycoprotein VI, Prothrombin, and Urokinase Type Plasminogen Activator. Plasminogen has the highest pipeline products.

Pulmonary Embolism Pipeline Market, by Target

Pulmonary Embolism Pipeline Market, by Target

For more target insights, download a free report sample

Key MoA in the Pulmonary Embolism Pipeline Market

The key MoA in the pulmonary embolism pipeline market are Plasminogen Activator, Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Platelet Glycoprotein VI Inhibitor, Prothrombin Inhibitor, and Urokinase Type Plasminogen Activator Replacement. Plasminogen Activator has the highest number of pipeline products.

Pulmonary Embolism Pipeline Market, by MoA

Pulmonary Embolism Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Pulmonary Embolism Pipeline Market

The key RoA in the pulmonary embolism pipeline market are intravenous, oral, subcutaneous, topical, and transdermal. Intravenous has the highest number of pipeline products.

Pulmonary Embolism Pipeline Market, by RoA

Pulmonary Embolism Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Pulmonary Embolism Pipeline Market

The key molecule types in the pulmonary embolism pipeline market are recombinant enzyme, monoclonal antibody, and small molecule. Recombinant enzyme has the highest number of pipeline products.

Pulmonary Embolism Pipeline Market, by Molecule Type

Pulmonary Embolism Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the Pulmonary Embolism Pipeline Market

The key companies in the pulmonary embolism pipeline market are Acticor Biotech SAS, Anthos Therapeutics Inc, Bio-Synectics Inc, China Resources Emde Biological Pharmaceutical Co Ltd, Indiana Lysis Technologies LLC, Kolmar Korea Co Ltd, Supergene LLC, Tasly Pharmaceutical Group Co Ltd, Techfields Pharma Co Ltd, Tianjin Pharmaceuticals Group Co Ltd, and Verseon Corp.

Market report overview

Key targets Plasminogen, Coagulation Factor X, Coagulation Factor XI, Platelet Glycoprotein VI, Prothrombin, and Urokinase Type Plasminogen Activator
Key MoA Plasminogen Activator, Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Platelet Glycoprotein VI Inhibitor, Prothrombin Inhibitor, and Urokinase Type Plasminogen Activator Replacement
Key RoA Intravenous, Oral, Subcutaneous, Topical, and Transdermal
Key molecule types Recombinant Enzyme, Monoclonal Antibody, and Small Molecule
Key companies Acticor Biotech SAS, Anthos Therapeutics Inc, Bio-Synectics Inc, China Resources Emde Biological Pharmaceutical Co Ltd, Indiana Lysis Technologies LLC, Kolmar Korea Co Ltd, Supergene LLC, Tasly Pharmaceutical Group Co Ltd, Techfields Pharma Co Ltd, Tianjin Pharmaceuticals Group Co Ltd, and Verseon Corp

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acticor Biotech SAS
Anthos Therapeutics Inc
Bio-Synectics Inc
China Resources Emde Biological Pharmaceutical Co Ltd
Indiana Lysis Technologies LLC
Kolmar Korea Co Ltd
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Embolism – Overview

Pulmonary Embolism – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pulmonary Embolism – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Embolism – Companies Involved in Therapeutics Development

Acticor Biotech SAS

Anthos Therapeutics Inc

Bio-Synectics Inc

China Resources Emde Biological Pharmaceutical Co Ltd

Indiana Lysis Technologies LLC

Kolmar Korea Co Ltd

Supergene LLC

Tasly Pharmaceutical Group Co Ltd

Techfields Pharma Co Ltd

Tianjin Pharmaceuticals Group Co Ltd

Verseon Corp

Pulmonary Embolism – Drug Profiles

abelacimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs for Pulmonary Embolism – Drug Profile

Product Description

Mechanism Of Action

glenzocimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

KKM-183A – Drug Profile

Product Description

Mechanism Of Action

reteplase – Drug Profile

Product Description

Mechanism Of Action

rivaroxaban – Drug Profile

Product Description

Mechanism Of Action

Staphylokinase – Drug Profile

Product Description

Mechanism Of Action

History of Events

TF-0023 – Drug Profile

Product Description

Mechanism Of Action

urokinase – Drug Profile

Product Description

Mechanism Of Action

History of Events

VE-2851 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Zifa-01 – Drug Profile

Product Description

Mechanism Of Action

Pulmonary Embolism – Dormant Projects

Pulmonary Embolism – Discontinued Products

Pulmonary Embolism – Product Development Milestones

Featured News & Press Releases

Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs

Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Pulmonary Embolism, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pulmonary Embolism – Pipeline by Acticor Biotech SAS, 2022

Pulmonary Embolism – Pipeline by Anthos Therapeutics Inc, 2022

Pulmonary Embolism – Pipeline by Bio-Synectics Inc, 2022

Pulmonary Embolism – Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2022

Pulmonary Embolism – Pipeline by Indiana Lysis Technologies LLC, 2022

Pulmonary Embolism – Pipeline by Kolmar Korea Co Ltd, 2022

Pulmonary Embolism – Pipeline by Supergene LLC, 2022

Pulmonary Embolism – Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022

Pulmonary Embolism – Pipeline by Techfields Pharma Co Ltd, 2022

Pulmonary Embolism – Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2022

Pulmonary Embolism – Pipeline by Verseon Corp, 2022

Pulmonary Embolism – Dormant Projects, 2022

Pulmonary Embolism – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Pulmonary Embolism, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Pulmonary Embolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pulmonary Embolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Pulmonary Embolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.